Jacobsson L, Von Knorring L, Mattsson B, Perris C, Rapp W, Edenius B, Kettner B, Magnusson K E, Villemoes P
Acta Psychiatr Scand. 1976 Aug;54(2):113-24. doi: 10.1111/j.1600-0447.1976.tb00103.x.
In a controlled trial of penfluridol and thiothixene as maintenance drugs in patients with chronic schizophrenic syndromes, some improvement over previous neuroleptics was seen with both drugs. This improvement was mainly evident in variables concerned with participation in social activities as assessed with the S-scale and by ward behaviour. The drug dosages necessary were very low and gave few and easily manageable side-effects. There was no significant difference between penfluridol and thiothixene. Penfluridol has the clear practical advantage of being the only long-acting drug for oral administration so far available.
在一项将五氟利多和硫利达嗪作为慢性精神分裂症综合征患者维持用药的对照试验中，两种药物均显示出比先前使用的抗精神病药物有一定改善。这种改善主要体现在通过S量表评估以及病房行为所反映的与参与社会活动相关的变量上。所需药物剂量非常低，且副作用少且易于控制。五氟利多和硫利达嗪之间没有显著差异。五氟利多具有明显的实际优势，即它是目前唯一可用的口服长效药物。
